BFI Infinity Ltd. Makes New $4.31 Million Investment in Biogen Inc. $BIIB

BFI Infinity Ltd. purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,095 shares of the biotechnology company’s stock, valued at approximately $4,313,000. Biogen comprises 2.1% of BFI Infinity Ltd.’s investment portfolio, making the stock its 15th largest holding.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Biogen in the second quarter valued at about $3,453,878,000. Primecap Management Co. CA acquired a new stake in shares of Biogen in the 2nd quarter valued at about $3,274,304,000. Wellington Management Group LLP lifted its holdings in Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after buying an additional 155,828 shares during the last quarter. Amundi boosted its holdings in Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after purchasing an additional 726,004 shares during the period. Finally, Legal & General Group Plc bought a new stake in shares of Biogen during the 2nd quarter valued at about $322,640,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Price Performance

BIIB opened at $235.35 on Friday. The stock has a market capitalization of $34.77 billion, a P/E ratio of 41.65, a price-to-earnings-growth ratio of 2.57 and a beta of 0.09. Biogen Inc. has a one year low of $138.00 and a one year high of $240.99. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The company’s 50 day simple moving average is $219.47 and its 200-day simple moving average is $203.65.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the business posted $5.47 earnings per share. Biogen’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts anticipate that Biogen Inc. will post 12.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Stifel Nicolaus set a $242.00 price objective on Biogen in a research report on Thursday, September 10th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $190.00 to $235.00 in a report on Monday, July 13th. Jefferies Financial Group reiterated a “buy” rating on shares of Biogen in a report on Monday, July 13th. HSBC upped their price target on shares of Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Finally, UBS Group increased their price target on shares of Biogen from $240.00 to $270.00 and gave the company a “buy” rating in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $236.04.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.